GlobeNewswire Inc.··NaAgomab Secures U.S. Patent for IPF Treatment AGMB-447 Through 2041
Agomab Therapeutics gains patent protection for AGMB-447, an inhaled lung-targeted therapy for idiopathic pulmonary fibrosis, with Phase 1b results expected in 2026.
AGMBintellectual propertyPhase 1b study